No Data
Capricor Stock Rallies 20% on DMD Data Presentation Update
Wave Life Sciences Is Maintained at Sector Perform by RBC Capital
RBC Raises Price Target on WAVE Life Sciences to $7 From $5, Keeps Sector Perform Rating, Speculative Risk
B.Riley Financial Maintains Wave Life Sciences(WVE.US) With Buy Rating, Raises Target Price to $19
B. Riley Adjusts WAVE Life Sciences' PT to $19 From $11, Maintains Buy Rating
Better Biotech Stock: Wave Life Sciences Vs. Sarepta Therapeutics